Amber Griffies

P1163 ALL-ORAL THERAPY WITH DACLATASVIR IN COMBINATION WITH ASUNAPREVIR AND BMS-791325 FOR TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE 4 INFECTION

T. Hassanein, P. Thuluvath, L. Webster, 2014 .

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants

Sun Ku Lee, Ang Liu, B. Murthy, 2017, European Journal of Clinical Pharmacology.

A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.

T. Hassanein, P. Thuluvath, L. Webster, 2015, Journal of hepatology.

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants

Sun Ku Lee, Ang Liu, B. Murthy, 2017, European Journal of Clinical Pharmacology.

A Pooled Analysis of Pharmacokinetic Variability Information for Common Probe Substrates Used in Drug-Drug Interaction Studies

Chunsheng He, R. Adamczyk, Amber Griffies, 2018, Pharmacology.